Fresenius Kabi, a division of Fresenius, and the Association for the Advancement of Blood & Biotherapies (AABB) are excited to announce the commencement of the 19th annual Blood Collectors Week,…
Daiichi Sankyo Europe (Daiichi Sankyo) has reinforced its commitment to addressing unmet needs and disparities in cardiovascular care by emphasizing the differences in treatment and outcomes among diverse patient groups.…
Arrowhead Pharmaceuticals, Inc. (NASDAQ: ARWR) has announced the results from its Phase 3 PALISADE study, which investigated the efficacy of the drug plozasiran in patients with familial chylomicronemia syndrome (FCS).…
Anthos Therapeutics, Inc., a cutting-edge clinical-stage biopharmaceutical company focused on developing innovative treatments for cardiovascular and metabolic diseases, announced significant findings from the AZALEA-TIMI 71 study at the European Society…
The NBI-‘568-SCZ2028 dose-finding study successfully met its primary endpoint with the once-daily 20 mg dose. This dose showed a significant and clinically meaningful reduction in the Positive and Negative Syndrome…
ScaleReady™, in collaboration with Wilson Wolf Manufacturing, Bio-Techne Corporation (NASDAQ: TECH), and CellReady™, is thrilled to announce that Dr. Steve Feldman, Scientific Director and Site Head of Stanford Medicine’s Laboratory…
Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura) has announced that the European Commission has granted Marketing Authorization for PADCEV™ (enfortumab vedotin, an antibody-drug conjugate [ADC]) in combination…
Moderna, Inc. (NASDAQ) has announced the launch of its new awareness initiative, “Do It For You & Them,” aimed at boosting COVID-19 vaccination rates across the United States. This campaign…
Chugai Pharmaceutical Co., Ltd. [Head Office: Tokyo, President and CEO: Osamu Okuda] and LTL Pharma Co., Ltd. [Head Office: Tokyo, President and Representative Director: Tetsuo Ito] have announced an agreement…
Chugai Pharmaceutical Co., Ltd. (TOKYO: 4519) has announced that the Ministry of Health, Labour and Welfare (MHLW) has approved Alecensa® (generic name: alectinib) for the additional indication of “adjuvant therapy…
Merck, a leading science and technology company, has announced that the first patient has been dosed in the Phase III MyClad trial (NCT06463587). This trial aims to evaluate the efficacy…
GSK plc (LSE/NYSE: GSK) has announced that the European Commission has authorized Arexvy, a recombinant adjuvanted respiratory syncytial virus (RSV) vaccine, for active immunization to prevent lower respiratory tract disease…